Archive · 2 Oct 2025
India's Pharma Industry: Navigating US Tariffs with AI & Diplomacy
The US imposed a 100% tariff on some imported medicines from India.
This could hurt India's $10 billion pharma business.
The US wants companies to make drugs in America instead.
India can respond by using artificial intelligence to make processes more efficient.
They can also look for new markets and negotiate deals with the US.
India needs to act fast to stay competitive.
The US implemented a 100% tariff on branded and patented pharmaceutical imports.
This action jeopardizes India's $10 billion pharmaceutical export sector.
The US aims to encourage domestic pharmaceutical manufacturing.
India can use AI and new markets to maintain competitiveness.
India needs to pursue diplomacy to secure its role in global pharma.
- Who
- India, US, Pharmaceutical Companies
- What
- US tariffs on Indian pharma products, India's response
- When
- October 1, 2025
- Where
- United States, India
- Why
- US protectionist trade policy, to reduce dependence on foreign imports, and to encourage domestic manufacturing.
India
US
Trade Policy
India
Favor open trade and reduce trade barriers.
US
Implement tariffs to protect domestic industry.
- US Tariff
- 100% on branded/patented pharma imports
- Targeted Products
- Branded and patented medications
- India's US Pharma Exports
- $10 Billion at Risk
- Key Strategy
- AI Integration, Market Diversification
- Proposed Actions
- MRAs, Regional Manufacturing, Trade Diplomacy
- AI Application
- Accelerate drug development, optimize supply chains
Sources
Trump’s drug tariff has spared most of China’s drugmakers for now but there may be worse to come
Donald Trump administration delays 100% tariff on brand-name drug imports, still ‘being worked on’
Donald Trump's Pfizer deal could change how governments tackle medicine prices
